Oftalmol Zh.2009;5:64-69.

http://doi.org/10.31288/oftalmolzh200956469

MODERN ASPECTS OF IMMONOSUPPRESSIVE THRERAPY OF ENDOGENIC UVEITES

Zhaboedov D. G., Ivanova N. V., Kopaenko A. I.

Kyev, Ukraine

The paper presents data of modern studies on application of immunosuppressive therapy in the treatment of severe endogenic uveitis. The results of the treatment with modern immunosuppressants are analyzed: inhibitors of tumour necrosis factor, antibodies to cytokine receptors and interferon a2a.

 

References

1.Павлюченко К. П., Кравцова Н. В. Исследование роли свободнорадикальных соединений в патогенезе эндогенного увеита // Офтальмол. журн. — 2006. — № 1. — С. 44-49.

2.Савко В. В., Нарицына Н. И., Коновалова Н. В. Основные этиологические формы эндогенных увеитов: клиника, диагностика, лечение // Офтальмол. журн. — 2006. — № 1. — С. 58-62.

3.Катаргина Л. А., Архипова Л. Т. Увеиты: патогенетическая иммуносупрессивная терапия. — М., 2004. — 100 с.

4.Шевчук Н. Е., Мальханов В. Б., Зайнутдинова Г. X. Содержание сосудисто-эндотелиального фактора роста и популяции лимфоцитов в крови больных увеитами различной этиологии // Офтальмол. журн. — 2007. — № 5. — С. 23-27.

5.Accorinti M., Pirraglia M. P., Paroli M. P. et al. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease // Jpn. J. Ophthalmol. — 2007. — Vol. 51. — P. 191-196.

Crossref   PubMed

6.Ardoin S. P., Kredich D., Rabinobich E. et al. Infliximab to treat chonic noninfectious uveitis in children: retrospective case with long-term follow-up // Am. J. Ophthalmol. — 2007. — Vol. 144. — P. 844-849.

Crossref    PubMed 

7.Bezditko P. A., Vlasko H. V., Mukcha I. D. The comparative analysis of application of the inravitreal triamcinolone and disrosopan in the treatment of the patients with cho-rioretinitis // Abstract book of the Joint Congress of SOE/ AAO. — Veinna, Austria, 2007. — P. 227.

8.Biester S., Deuter C., Michels H. et al. Adalimumab in the therapy of uveitis in Childhood // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 319-324.

Crossref   PubMed  

9.Bodaghi B., Gendron G., Weschler B. et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 335-433.

Crossref   PubMed

10.Buggage R. R., Levy-Clarke G., Sen H. N. et al. Adouble-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease // Ocul. Immunol. Inflamm. — 2007. — Vol. 15. — P. 63-70.

Crossref   PubMed 

11.Cekmen M., Everklioglu C., Er H. et al. Vascular endo-thelial growth factor levels are increased and associated with disease activity in patients with Behcet's syndrome // Int. J. Derrmatol. — 2003. — Vol. 42, № 11. — P. 870875.

Crossref   PubMed

12.Cordoro Coma M., Sorbin L., Onal S., Foster C. S. Intravit-real bevacizumab for treatment of uveitic macular edema // Ophthalmology. — 2007. — Vol. 114 (8). — P. 1574-1579.

Crossref   PubMed

13.Delyfer M. N., Rougier M. B., Hubschman J. P. et al. Cy-tomegalovirus retinitis following intravitreal injection of triamcinolone: report of two cases //Acta Ophthalmol. Scand. — 2007. — Vol. 85. — P. 681-683.

Crossref   PubMed 

14.Dev S., McCallum R. M., Jaffee G. J. Methotrexate treat-ment for sarcoid-associated panuveitis // Ophthalmology. — 1999. — Vol. 106. — P. 111.

Crossref  

15.Doycheva D., Deuter C., Stuebiger N. et al. Mycopheno-late mofetil in the treatment of uveitis in children // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 180-184.

Crossref   PubMed

16.Fine H. F., Baffi J., Reed G. F. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema // Am. J. Ophthal. —  2001. — Vol. 132, № 5. — P. 794-796.

Crossref   

17.Fonollosa A., Segura A., Giralt J., Garcia-Arumi J. Tu-berculous uveitis after treatment with etanercept // Graefes Arch. Clin. Exp. Ophthalmol. — 2007. — Vol. 245. — P. 1397-1399.

Crossref   PubMed

18.Foster C. S., Baer J. C., Raizman M. B. Therapeutic re-sponses tosystemic immunosuppressive chemotherapy agents in patients with Behcet's Disease // Basic and Clinical Aspect. — New York, Marcel Dekker, 1991. — P. 581588.

19.Foster C. S., Barret F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis irido-cyclitis // Ophthalmology. — 1993. — Vol. 100. — P. 809-817.

Crossref   

20.Foster C. S., Vitale A. T. Diagnosis and treatment of uveitis // Philadelphia, W. B. Saunders. — 2002. — P. 177-214.

21.Gallagher M., Quinones K., Cervantes-Castaneda R. A. et al. Biological response modifier therapy for refractory childhood uveitis // Br. J. Ophthalmol. — 2007. — Vol. 91. — P. 1341-1344.

Crossref   PubMed  

22.Galor A., Perez V. L., Hammel J. P., Lowder C. Y. Dif-ferential effectiveness of etanercept and infliximab in the treatment of ocular inflammation // Ophthalmology. — 2006. — Vol. 113. — P. 2317-2323.

Crossref    PubMed  

23.Guenudry J., Wechsler B., Terrada C. et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease // Am. J. Ophthalmol. — 2008. — Vol. 146, № 6. — P. 837-844.

Crossref   PubMed

24.Imrie F. R., Dick A. D. Biologics in the treatment of uveitis // Curr. Opin. Ophthalmol. — 2007. — Vol. 18. — P. 481-486.

Crossref   PubMed

25.Jap A., Chee S. P. Immunosuppressive therapy for ocular diseases // Curr. Opin. Ophthalmol. — 2008. — Vol. 19 (6). — P. 535-540.

Crossref    PubMed  

26.Jonas J. B., Spandau U. H., Rensch F. et al. Infectious and noninfectious endophthalmitis after intravitreal beva-cizumab // J. Ocul. Pharmacol. Ther. — 2007. — Vol. 23 (3). — P. 240-242.

Crossref    PubMed 

27.Jovanovic S., Vukosavljevic M., Stanojevic-Paovic A., Petrovic M. The effects of posterior subtenos's casule triamcinolone injection on macular edema in patients with uveitis // Abstracts book of Joint Congress of SOE/ AAO. — Vienna, Austria, 2007. — P. 229.

28.Kozak Y., Verwaerde C. Cytokines in immunotherapy of experimental uveitis // Int. Rev. Immunol. — 2002. — Vol. 21 (2-3). — P. 231-253.

Crossref   PubMed  

29.Laomba M. S., Martin C. M., Chamond R. R. et al. Aqueous and serum interferon y, interleukin (IL) 2, IL-4 and IL-10 in patients with uveitis // Arch. Ophthamol. — 2000. — Vol. 118, № 6. — P. 768-782.

Crossref    PubMed

30.Lim L., Suhler E. B., Smith J. R. Biologic therapies for inflammatory eye disease // Clin. Experiment Ophthalmol. — 2006. — Vol. 34. — P. 365-374.

Crossref   PubMed  

31.Mackensen F., Heinz C., Becker M. D., Heiligenhaus A. Intravitreal bevacizumab (avastin) as a tretament for re-fractory macular edema in patients with uveitis: a pilot study // Retina. — 2008. — № 28 (1). — P. 4145.

Crossref   PubMed  

32.Mushtaq B., Saeed T., Situnayake R. D., Murray P. I. Adalimumab for sightthreatening uveitis in Behcet's disease // Eye. — 2007. — Vol. 21. — P. 824-825.

Crossref   PubMed   

33.Niccoli L., Nannini C., Benucci M. et al. Long-term effi-cacy of infliximab inrefractory posterior uveitis of Behcet's disease: a 24-month follow-up study // Rheumatology. — 2007. — Vol. 46. — P. 1161-1164.

Crossref   PubMed

34.Nussenblatt R. B., Palestine A. G., Chan C. C. et al. Ran-domized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis // Am. J. Ophthalmol. — 1991. — Vol. 112. — P. 38-146.

Crossref 

35.Nussenblatt R. B., Peterson J. S., Foster C. S. et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series // Ophthalmology. — 2005. — Vol. 112. — P. 764-770.

Crossref   PubMed

36.Ohno S., Nakamura S., Hori S. et al. Efficacy, safety, and pharmacokinetics of multiple administration of infiximab in Behcet's disease with refractory uveoretinitis // J. Rheumatol. — 2004. — Vol. 31. — P. 1362-1368.

37.Peter J. Mc Cluskey, Hamish M. A. Management of chronic uveitis // Br. Med. J. — 2000. — Vol. 320. — P. 555-558.

Crossref  PubMed

38.Pilli S., Kotsolis A., Spaide R. F. et al. Endophthalmitis associated with intravitreal antivascular endothelial growth factor therapy injections in an office setting // Am. J. Ophthalmol. — 2008. — Vol. 145 (5). — P. 879-882.

Crossref  PubMed

39.Plskova J., Greiner K., Forrester J. V. Interferon-alfa as an effective treatment for noninfectious posterior uveitis and papanuveitis // Am. J. Ophthalmol. — 2007. — Vol. 144. — P. 55-61.

Crossref  PubMed 

40.Rothova A. Corticosteroids in uveitis // Ophthalmol. Clin. North. Am. — 2002. — Vol. 15 (3). — P. 389-394.

Crossref   

41.Saidel M. A., Berrern J., Margolis T. P. Cytomegalovi-rus retinitis after intravitrous triamcinolone in an immu-nocompetent patient // Am. J. Ophthalmol. — 2005. — Vol. 140. — P. 1141-1143.

Crossref   PubMed

42.Saurenmann R. K., Levin A. V., Rose J. B. et al. Tumour nectosis factor a inhibitors in the treatment of childhood uveitis // Rheumatology. — 2006. — Vol. 45. — P. 982-989.

Crossref   PubMed 

43.Sfikakis P. P., Kaklaminis P. H., Elezoglou A. et al. Inflix-imab for recurrent, sightthreatening ocular inflammation in Adamantiades-Behcet's disease // Ann. Intern. Med. — 2004. — Vol. 140. — P. 404-406.

Crossref   PubMed 

44.Sfikakis P. P., Markomichelakus N., Alpsoy E. et al. Anti-TNF therapy in the management of Behcet's disease: re-view and basis for recommendations // Rheumatology. — 2007. — Vol. 46. — P. 736-741.

Crossref   PubMed

45.Shah S. S., Lowder C. Y., Fox D. A. et al. Low-dose meth-otrexate therapy for ocular inflammatory disease // Oph-thalmology. — 1992. — Vol. 99. — P. 1419-1423.

Crossref  

46.Siepmann K., Huber M., Stubinger N. et al. Mycophe-nolate mofetil is a highly effective and safe immunosup-pressive agent for the treatment of uveitis: a retrospective analysis of 106 patients // Graefes Arch. Clin. Exp. Ophthalmol. — 2006. — Vol. 244. — P. 788-794.

Crossref    PubMed

47.Sobrin L., Huang J. J., Christen W. et al. Daclizumab for treatment of birdshot Chorioretinopathy // Arch. Oph-thalmol. — 2008. — Vol. 126. — P. 186-191.

Crossref   PubMed

48.Sobrin L., Kim E. C., Christen W. et al. Infiximab therapy for the treatment of refractory ocular inflammatory disease // Arch. Ophthalmol. — 2007. — Vol. 125. — P. 895-900.

Crossref   PubMed 

49.Towler H. M. A., Lighman S. L., Forrester J. V. Combination low dose cyclysporine A and steroid therapy in chronic intraocular inflammation // Eye. —   1990. — Vol. 4. — P. 514-520.

Crossref   PubMed

50.Tynjala P., Lindhal P., Honkanen V. et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopatihc arthritis // Ann. Rheum. Dis. — 2007. — Vol. 66. — P. 548-550.

Crossref   PubMed  

51.Vazquez-Cobian L. B., Flynn T., Lehman T. J. A. Adali-mumab therapy for childhood uveitis // J. Pedieat. — 2006. — Vol. 149. — P. 572-575.

Crossref   PubMed  

52.Whitcup S. M., Salvo E. C., Nussenblatt R. B. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease // Am. J. Ophthalmol. — 1994. — Vol. 118. — P. 39-45.

Crossref   

53.Yazici J., Pazarli H., Barnes C. G. et al. A controlled trial of azathioprine in Behcet's syndrome // N. Engl. J. Med. — 1990. — Vol. 332. — P. 281-285.

Crossref    PubMed